CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Shares Sold by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. lowered its position in shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) by 17.1% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 468,109 shares of the company’s stock after selling 96,251 shares during the quarter. Pinnacle Associates Ltd. owned about 4.09% of CollPlant Biotechnologies worth $2,324,000 at the end of the most recent reporting period.

CollPlant Biotechnologies Trading Up 1.8 %

NASDAQ:CLGN opened at $3.75 on Friday. CollPlant Biotechnologies Ltd. has a 12 month low of $3.64 and a 12 month high of $6.99. The stock has a 50 day moving average of $4.67 and a two-hundred day moving average of $5.06. The firm has a market cap of $42.96 million, a P/E ratio of -2.44 and a beta of 0.31.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its quarterly earnings data on Tuesday, August 20th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). CollPlant Biotechnologies had a negative return on equity of 65.98% and a negative net margin of 2,535.70%. The firm had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.70 million. On average, research analysts forecast that CollPlant Biotechnologies Ltd. will post -1.44 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a report on Wednesday, August 21st. EF Hutton Acquisition Co. I upgraded CollPlant Biotechnologies to a “strong-buy” rating in a research note on Monday, August 5th.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.